Key points are not available for this paper at this time.
This Viewpoint reviews the development of immune checkpoint inhibitors as a new drug class for treating cancer, and discusses future directions including development of commercial assays for identifying response-to-treatment biomarkers and the use of combination regimens to improve response.
Suzanne L. Topalian (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: